Form 4: BrainStorm Cell Therapeutics Director Option Grant

Director Stacy Lindborg was granted 150,000 stock options in BrainStorm Cell Therapeutics Inc. (BCLI).

Summary

• Director Stacy Lindborg received a grant of 150,000 stock options to purchase common stock.
• The options have an exercise price of $0.70 per share.
• The grant was issued under the Issuer's 2014 Stock Incentive Plan.
• Vesting occurs in two tranches: 50% on the grant date and 50% on the six-month anniversary.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon exercise of the options.

Risks

• Market price volatility of BCLI common stock could impact the value of the options.
• Vesting is contingent upon the director remaining with the company.

Future Outlook

The options expire on 02/26/2036, with full vesting expected by 08/26/2026, provided the director remains with the company.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practice in the biotechnology sector to ensure long-term commitment and alignment with shareholder value.

Comparison to Industry Standards

• The use of a 2014 Stock Incentive Plan is consistent with standard equity compensation structures for small-cap biotech firms.
• Vesting schedules involving immediate and time-based components are common for board-level compensation.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if options are exercised.

Next Steps

• Vesting of the remaining 50% of the options on 08/26/2026.

Key Dates

Keywords

BCLI, BrainStorm Cell Therapeutics, Form 4, Stock Options, Insider Transaction, Director Compensation